AIM ImmunoTech's Ampligen Advances in Pancreatic Cancer Treatment Amidst Financial Challenges

AIM ImmunoTech is advancing Ampligen for pancreatic cancer treatment, with promising safety and efficacy data from the DURIPANC trial. Despite financial challenges, AIM is focused on FDA approval, which could enhance its market position. The company faces risks, including poor financial strength and low institutional ownership. Valuation metrics suggest potential undervaluation, with a P/S ratio close to its five-year low and an RSI of 24.55 indicating oversold conditions.